Companies

In January 2005, Vitae Pharmaceuticals, formerly Concurrent Pharmaceuticals, announced its new corporate branding to clearly mark its strategic evolution to a product-focused drug development company with a robust pipeline of novel clinical candidates. In addition, Vitae announced that it secured $34 million in equity financing to accelerate the company's product programs in cancer, dermatology and cardiovascular disease. Vitae is singularly product-focused. The company discovers and advances promising compounds to create a robust and sustainable pipeline of high impact drugs. Vitae Pharmaceuticals' strategies to achieve this goal are to: - Focus on well validated targets that align with significant unmet medical needs and large potential market opportunities; - Combine the expertise of world-class scientists, who have the proven ability to discover and develop successful drugs, with unique and proprietary, drug design technologies; - Seek strategically appropriate partnerships with global pharmaceutical companies that will contribute expertise and resources to accelerate its programs; - Continue to build upon and leverage a world-class team which has considerable pharmaceutical experience in creating value by discovering, developing and successfully commercializing significant drugs.